Trial
NCT05048056
Phase 2 Study of Efficacy and Safety of AK120, in Subjects With Moderate-to-Severe Atopic Dermatitis
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Akesobio Australia Pty Ltd
Collaborators
—
Condition
Atopic Dermatitis
Intervention
Placebo
Why stopped
Clinical study and development strategy adjustment
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-02-26